LYTIX Share Price Performance
NOK 0
-7.94 (-100.00%)
Price NOK 0
Fair ValueNOK 15.00
Share Pricen/a
Lytix Biopharma ASA Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
LYTIX Community Narratives
AN
Fair Value
·Fair Value NOK 15 44.0% undervalued intrinsic discount
Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Lytix Biopharma
44.0% undervalued intrinsic discount
Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects
View narrativeAN
Published 25 May
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects
Fair Value: NOK 15 44.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lytix Biopharma ASA Key Details
About LYTIX
- Founded
- 2003
- Employees
- 14
- CEO
- WebsiteView website
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.
